Ontology highlight
ABSTRACT:
SUBMITTER: de Man FM
PROVIDER: S-EPMC6593619 | biostudies-literature | 2019 Jun
REPOSITORIES: biostudies-literature
de Man Femke M FM Hussaarts Koen G A M KGAM de With Mirjam M Oomen-de Hoop Esther E de Bruijn Peter P van Halteren Henk K HK van der Burg-de Graauw Nicole C H P NCHP Eskens Ferry A L M FALM van Gelder Teun T van Leeuwen Roelof W F RWF Mathijssen Ron H J RHJ
Clinical pharmacology and therapeutics 20190210 6
Regorafenib exposure could potentially be influenced by an interaction with acid-reducing drugs. In this crossover trial, patients were randomized into two sequence groups consisting of three phases: regorafenib intake alone, regorafenib with concomitant esomeprazole, and regorafenib with esomeprazole 3 hours prior. The primary end point was the relative difference (RD) in geometric means for regorafenib 0-24-hour area under the concentration-time curve (AUC<sub>0-24h</sub> ) and was analyzed by ...[more]